ReviewEMBO molecular medicine2015
Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
Review in EMBO molecular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Sarcomere analysis in human cardiomyocytes by computing radial frequency spectra.Biological chemistry · 2025Article
- Cell Reprogramming, Transdifferentiation, and Dedifferentiation Approaches for Heart Repair.International journal of molecular sciences · 2025Review
- Enhancing Cardiomyocyte Purity through Lactate-Based Metabolic Selection.Tissue engineering and regenerative medicine · 2025Article
- Nissl Granules, Axonal Regeneration, and Regenerative Therapeutics: A Comprehensive Review.Cureus · 2023Review
- The role of metabolism in directed differentiation versus trans-differentiation of cardiomyocytes.Seminars in cell & developmental biology · 2022Review
- Inhibition of Rho-associated protein kinase improves the survival of human induced pluripotent stem cell-derived cardiomyocytes after dissociation.Experimental and therapeutic medicine · 2020Article
- Reprogramming of Keratinocytes as Donor or Target Cells Holds Great Promise for Cell Therapy and Regenerative Medicine.Stem cell reviews and reports · 2019Review
- The Hox transcription factor Ubx stabilizes lineage commitment by suppressing cellular plasticity ineLife · 2019Article
- Stem Cell Therapies in Cardiovascular Disease.Journal of cardiothoracic and vascular anesthesia · 2019Review
- Metabolism Is a Key Regulator of Induced Pluripotent Stem Cell Reprogramming.Stem cells international · 2019Review
- Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Review
- Harnessing cell pluripotency for cardiovascular regenerative medicine.Nature biomedical engineering · 2018Review
- Article
- Downregulation of LGR5 Expression Inhibits Cardiomyocyte Differentiation and Potentiates Endothelial Differentiation from Human Pluripotent Stem Cells.Stem cell reports · 2017Article
- Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology.Veterinary world · 2017Review
- The Tumorigenicity of Multipotent Adult Germline Stem Cells Transplanted into the Heart Is Affected by Natural Killer Cells and by Cyclosporine A Independent of Its Immunosuppressive Effects.Frontiers in immunology · 2017Article
- Immunological Properties of Murine Parthenogenetic Stem Cells and Their Differentiation Products.Frontiers in immunology · 2017Article
- Oxymatrine inhibits aldosterone-induced rat cardiac fibroblast proliferation and differentiation by attenuating smad-2,-3 and-4 expression: an in vitro study.BMC complementary and alternative medicine · 2016Article
- Rebuilding the Damaged Heart: Mesenchymal Stem Cells, Cell-Based Therapy, and Engineered Heart Tissue.Physiological reviews · 2016Review
- Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Heart disease remains a leading cause of mortality and a major worldwide healthcare burden. Recent advances in stem cell biology have made it feasible to derive large quantities of cardiomyocytes for disease modeling, drug development, and regenerative medicine. The discoveries of reprogramming and transdifferentiation as novel biological processes have significantly contributed to this paradigm. This review surveys the means by which reprogramming and transdifferentiation can be employed to generate induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and induced cardiomyocytes (iCMs). The application of these patient-specific cardiomyocytes for both in vitro disease modeling and in vivo therapies for various cardiovascular diseases will also be discussed. We propose that, with additional refinement, human disease-specific cardiomyocytes will allow us to significantly advance the understanding of cardiovascular disease mechanisms and accelerate the development of novel therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.